Cue Biopharma (CUE) director Sarraf Pasha receives 21,800 RSU equity award
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Sarraf Pasha reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. director Sarraf Pasha received a grant of 21,800 restricted stock units (RSUs) of common stock. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service. Following this award, Pasha holds 32,595 shares (on a post–1-for-30 reverse split basis effective April 22, 2026).
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Sarraf Pasha
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 21,800 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 32,595 shares (Direct, null)
Footnotes (1)
- Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date. Total holdings held after the transaction reflects a 1-for-30 reverse split of the issuer's stock effected on April 22, 2026.
Key Figures
RSUs Granted: 21,800 RSUs
Grant Price: $0.0000 per share
Holdings After Transaction: 32,595 shares
+3 more
6 metrics
RSUs Granted
21,800 RSUs
Equity award of restricted stock units to director Sarraf Pasha
Grant Price
$0.0000 per share
RSUs granted as compensation, not purchased for cash
Holdings After Transaction
32,595 shares
Total Cue Biopharma common shares held after the RSU grant
Reverse Split Ratio
1-for-30
Reverse split of Cue Biopharma stock effective April 22, 2026
First Vesting Date
July 9, 2027
One-third of RSUs vest on this date, subject to continued service
Final Vesting Date
July 9, 2029
Final one-third of RSUs vest on this date, subject to continued service
Key Terms
restricted stock units ("RSUs"), reverse split, vesting
3 terms
restricted stock units ("RSUs") financial
"Represents the grant of restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
reverse split financial
"reflects a 1-for-30 reverse split of the issuer's stock"
A reverse split is when a company reduces the number of its outstanding shares by combining several existing shares into one new share, so the price per share rises proportionally while the company’s overall value stays the same. Investors care because it can make a stock appear more respectable or meet exchange rules — like turning many small coins into a single larger bill — but it can also signal financial trouble and often affects trading liquidity and investor perception.
vesting financial
"One-third of the shares subject to the RSUs vest on each of July 9, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Cue Biopharma (CUE) director Sarraf Pasha report in this Form 4?
Director Sarraf Pasha reported receiving a grant of 21,800 restricted stock units (RSUs) of Cue Biopharma common stock, with vesting in three equal annual installments starting in July 2027.
What are the vesting dates for Sarraf Pasha’s 21,800 Cue Biopharma (CUE) RSUs?
The 21,800 RSUs vest in three equal installments. One-third vests on July 9, 2027, one-third on July 9, 2028, and the final third on July 9, 2029, contingent on continued service.
Was cash paid for the Cue Biopharma (CUE) RSUs granted to Sarraf Pasha?
No purchase price was paid; the RSUs were granted at $0.0000 per share as an equity award, typical for director or employee equity compensation rather than an open-market stock purchase.
How did Cue Biopharma’s reverse split affect Sarraf Pasha’s reported holdings in this Form 4 for CUE?
The reported total of 32,595 shares reflects Cue Biopharma’s 1-for-30 reverse split effective April 22, 2026, meaning prior share amounts were proportionally reduced for reporting consistency.